Key result
Intravenous NKH477 increases cardiac index ~32% in severe heart failure.
Why the study?
The efficacy and safety of NKH477, a water soluble forskolin derivative, in patients with severe heart failure required evaluation.
Does intravenous NKH477 improve hemodynamics and what is the optimal dose in patients with severe heart failure?
Population
62 patients with severe heart failure
Comparison
NKH477 intravenous doses at 0.25, 0.5, and 0.75 μg/kg/min
Design
Multicenter open-label dose escalation study
Follow-up
Hourly dose escalation
Authors
Loading...
May support acute hemodynamic management in severe HF; hypothesis-generating and requires RCTs before practice change.
Does intravenous NKH477 improve hemodynamics and what is the optimal dose in patients with severe heart failure?
Absolute Event Rate: 3.25% vs 2.47%
p-value: p=<0.01
Intravenous NKH477 improves hemodynamics in severe heart failure, with an optimal clinical dose of 0.5 μg/kg/min balancing efficacy and safety.
Takano et al. (1997) studied Acute heart failure (n=62). NKH477 vs. Baseline was evaluated on Cardiac index at 0.5 µg/kg/min (L/min/m2) (p=<0.01). Intravenous NKH477 dose-dependently improved hemodynamics in patients with severe heart failure, increasing cardiac index from 2.47 to 3.25 L/min/m2 at the optimal dose of 0.5 µg/kg/min.